Table 1 |
|||||
|
Clinical details of rheumatoid arthritis patients |
|||||
|
Age (years) |
Sex |
Rheumatoid Factor |
Erosive disease |
Therapy |
DAS28 score |
|
|
|||||
|
Samples used to culture fibroblasts |
|||||
|
62 |
Female |
+ |
+ |
Methotrexate |
5.5 |
|
52 |
Female |
+ |
+ |
Methotrexate |
4.4 |
|
66 |
Male |
+ |
+ |
Etanercept, oral prednisolone |
5.5 |
|
71 |
Female |
+ |
+ |
D-penicillamine |
5.3 |
|
62 |
Female |
+ |
+ |
-- |
6.8 |
|
59 |
Female |
+ |
+ |
Methotrexate |
6.8 |
|
30 |
Female |
+ |
+ |
Azathioprine |
6.5 |
|
77 |
Male |
+ |
+ |
Sulphasalazine |
4.0 |
|
Samples used for confocal microscopy and flow cytometry |
|||||
|
72 |
Female |
+ |
+ |
Methotrexate |
-- |
|
73 |
Female |
+ |
+ |
Methotrexate |
-- |
|
73 |
Female |
+ |
+ |
Methotrexate, oral prednisolone |
-- |
|
62 |
Female |
-- |
-- |
Methotrexate, infliximab |
-- |
|
64 |
Female |
+ |
+ |
-- |
-- |
|
66 |
Female |
+ |
+ |
Methotrexate |
-- |
|
|
|||||
|
Parsonage et al. Arthritis Research & Therapy 2008 10:R47 doi:10.1186/ar2406 |
|||||
